Augusto Bondani, M.D., Ph.D. has held top-level positions in government, industry and academia. He has over 30 years of experience in the pharmaceutical industry. Prior to beginning his private consulting practice, he was Head of Drugs, Devices and all Health-Related Products for Mexico's Ministry of Public Health. Dr. Bondani advises us on all aspects of international regulatory affairs.

Stanley N. Cohen, M.D. is Professor of Genetics and Professor of Medicine at Stanford University School of Medicine. Dr. Cohen is the co-inventor, along with Herbert Boyer, of the break-through recombinant DNA cloning technology. Among his many scientific honors and awards are the National Medal of Science in 1988 and the National Medal of Technology in 1989. Dr. Cohen advises us on the isolation of VNO receptors and general biotechnology matters.

Elias James Corey, Ph.D. is Professor of Chemistry at Harvard University. Among his many scientific awards are the Nobel Prize in Chemistry in 1990 and the National Medal of Science in 1998. Dr. Corey's pioneering work revolutionized the ability of chemists to create synthetic versions of organic molecules in the laboratory, led to the discovery of many important new pharmaceuticals and improved the theoretical understanding of the mechanisms of action of these novel agents. Dr. Corey assists us in modeling new and improved compounds that are active on the VNO.

Ellen Freeman, Ph.D. is Research Professor and Co-Director of the Human Behavior and Reproduction Unit in the Department of Obstetrics and Gynecology at the University of Pennsylvania. Dr. Freeman currently serves on the Health Behavior and Prevention Review Committee, National Institute of Mental Health and also serves as reviewer for numerous scientific and professional journals. Dr. Freeman is recognized internationally as one of the leading researchers in the field of PMS. She assists us with our clinical development program on premenstrual syndrome.

Michael B. Liebowitz, M.D. is Associate Professor of Clinical Psychiatry at Columbia University, N.Y., Director of the Anxiety Disorders Clinic at the New York State Psychiatric Institute and Managing Director of the Medical Research Network. Dr. Liebowitz is recognized as one of the leading researchers in the field of anxiety disorders in the world. He is assisting us with the clinical development of our anxiety program.

George Rosenkranz, Dr. Sc. Tech. is the former Chairman, President and Chief Executive Officer of Syntex Corporation. At the time of his retirement from Syntex, he was appointed to the honorary post of Founding Chairman and Chairman of the Board Committee on Science. He has received numerous awards, including the Mexican National Prize in Pharmaceutical Sciences in 1994 and, from Panama, recognition as a commander, Order Vasco de Nunez de Balboa, in honor of his scientific and business achievements. The National Academy of Medicine of Mexico made him an honorary member of the academy in recognition of his contributions to science, medicine and business, and for helping the medical community through his dedication to teaching and scientific work at Syntex. Dr. Rosenkranz attended the Swiss Federal Institute of Technology in Zurich, earning an undergraduate degree in chemical engineering and a doctorate in technical sciences. He also holds an honorary degree from the University of the Americas, Mexico. Dr. Rosenkranz provides general scientific and business advice to us.

José Vicente Díaz-Sánchez, M.D., Ph.D. has held the position of Coordinator of the Pharmacokinetics Unit and the Infertility Unit at the National Institute of Nutrition, Department of Biology and Reproduction, in Mexico City. He has lectured and published extensively in the fields of endocrinology and contraception. The World Health Organization recently honored him for his collaborations on human reproduction. Dr. Díaz-Sánchez is studying the effects of pherines on the endocrine system.

Gustavo A. García de la Mora, Ph.D. is Professor of Chemistry at the Faculty of Chemistry of the National Autonomous University of Mexico. He has over 30 years of experience in the synthesis of organic compounds - particularly steroids. He consults for the World Health Organization and several chemical companies. Dr. García de la Mora is guiding the synthesis of new pherines at pilot and industrial scales.

Roger Whiting, Ph.D. is the President and Chief Scientific Officer of Roxro Pharma, a development stage pharmaceutical development company and has 29 years of experience in the pharmaceutical sector. At Syntex Corporation, Dr. Whiting held positions in pharmacology, and new drug discovery, evaluation and development. He was Senior Vice President and Head of the Neurobiology Business Unit at Roche Bioscience. He has published over 90 scientific papers and holds 15 patents. Dr. Whiting is advising us on new product development.